Targeted sequencing and molecular profiling of a papillary and cribriform clear cell intrahepatic cholangiocarcinoma reveals absence of selectable mutations

Gastroenterol Hepatol. 2019 Jun-Jul;42(6):374-375. doi: 10.1016/j.gastrohep.2018.08.006. Epub 2018 Oct 4.

[Article in English, Spanish]

Authors

Iban Aldecoa¹, Carla Montironi², Guillermo Madrigal Vargas³, Diego Alcaraz Nunes⁴, Rosa Miquel⁵, Miriam Cuatrecasas²

Affiliations

¹ Department of Pathology, Biomedical Diagnostic Center-CDB, Hospital Clinic - University of Barcelona, Barcelona, Spain. Electronic address: [email protected].
² Department of Pathology, Biomedical Diagnostic Center-CDB, Hospital Clinic - University of Barcelona, Barcelona, Spain.
³ Unidad de Patología Gastrointestinal, Hospital San Juan de Dios, San José, Costa Rica.
⁴ Department of Oncology, Clínica Diagonal, Barcelona, Spain.
⁵ Institute of Liver Studies, Liver Histopathology, King's College Hospital, London, UK.

PMID: 30293915
DOI: 10.1016/j.gastrohep.2018.08.006

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bile Duct Neoplasms / drug therapy
Bile Duct Neoplasms / genetics*
Bile Duct Neoplasms / pathology
Bile Duct Neoplasms / surgery
Cholangiocarcinoma / drug therapy
Cholangiocarcinoma / genetics*
Cholangiocarcinoma / pathology
Cholangiocarcinoma / surgery
Combined Modality Therapy
DNA, Neoplasm / genetics
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Fatal Outcome
Female
Hepatectomy
Humans
Middle Aged
Mutation
Organoplatinum Compounds / administration & dosage
Sequence Analysis, DNA

Substances

DNA, Neoplasm
Organoplatinum Compounds
Deoxycytidine

Supplementary concepts

gemcitabine-oxaliplatin regimen